Ustekinumab in Crohn's disease: evidence to date and place in therapy

scientific article

Ustekinumab in Crohn's disease: evidence to date and place in therapy is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1177/2040622316653306
P932PMC publication ID4935835
P698PubMed publication ID27433311

P50authorUri KopylovQ50913261
P2093author name stringTal Engel
P2860cites workInflammatory Bowel DiseaseQ22248115
Th17 plasticity and its changes associated with inflammatory bowel diseaseQ26775934
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's diseaseQ26825174
Natalizumab for active Crohn's diseaseQ28201431
Certolizumab pegol for the treatment of Crohn's diseaseQ28236746
Infliximab maintenance therapy for fistulizing Crohn's diseaseQ28246982
A genome-wide association study identifies IL23R as an inflammatory bowel disease geneQ28270603
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Q28280453
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialQ28296771
Epidemiology and natural history of inflammatory bowel diseasesQ29619945
Increased expression of interleukin 17 in inflammatory bowel diseaseQ29622829
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementQ30620977
Biologics in inflammatory bowel disease: what are the data?Q31017419
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.Q33823950
Role of cytokines in the pathogenesis of inflammatory bowel diseaseQ33896046
Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeuticsQ34141280
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseasesQ34181228
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialQ34275637
Vedolizumab as induction and maintenance therapy for Crohn's diseaseQ34365574
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trialQ34574245
Review of the safety and efficacy of ustekinumabQ34625984
Briakinumab for treatment of Crohn's disease: results of a randomized trialQ35670615
Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's diseaseQ35765082
Genetic origin of IBD.Q35787625
Immune dysfunction in inflammatory bowel diseaseQ36769500
Neuroimmunology of the gut: physiology, pathology, and pharmacologyQ37233795
Assessing response and loss of response to biological therapies in IBD.Q37856191
Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasisQ37929165
The future of inflammatory bowel disease therapy: where do we go from here?Q38072235
Ustekinumab: moving the target from psoriasis to Crohn's diseaseQ38177321
Update on ustekinumab for the treatment of Crohn's diseaseQ38238720
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experienceQ39164487
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort studyQ39869647
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.Q40472089
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseQ40503639
The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man.Q40542750
Pathogenesis and immune mechanisms of chronic inflammatory bowel diseasesQ41659087
Ustekinumab induction and maintenance therapy in refractory Crohn's diseaseQ42514321
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.Q42613896
Inflammatory bowel disease: etiology and pathogenesisQ47899867
Infliximab, azathioprine, or combination therapy for Crohn's diseaseQ56988763
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's diseaseQ56992312
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upQ85858615
Demyelination in a patient receiving ustekinumab for refractory Crohn's diseaseQ87364504
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectCrohn's diseaseQ1472
P304page(s)208-214
P577publication date2016-07-06
P1433published inTherapeutic advances in chronic diseaseQ26842871
P1476titleUstekinumab in Crohn's disease: evidence to date and place in therapy
P478volume7

Reverse relations

cites work (P2860)
Q90579983A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
Q99707492An immune therapy model for effective treatment on inflammatory bowel disease
Q48786898Diagnosis and management of inflammatory bowel disease in children.
Q38735477Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Q50782815Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Q47109861The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
Q39102244Update on the Use of Biologic Therapy in Ulcerative Colitis

Search more.